Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

ogram for the treatment of pain without constipation side effects.  NKTR-102 is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers.  NKTR-105 is in a Phase 1 clinical study in cancer patients with refractory solid tumors. Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India.  Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect Nektar's current views regarding the potential of its technology platform, the potential of NKTR-102 for breast cancer patients, preliminary results from the Phase 2 clinical trial of NKTR-102 in metastatic breast cancer patients, and the potential of certain other drug candidates in Nektar's pipeline.  These forward-looking statements involve substantial risks and uncertainties, including but not limited to one or more of the following: (i) NKTR-102 is in mid-stage clinical development and the risk of failure remains high and failure can unexpectedly occur at any stage for one or more of the cancer indications being studied (i.e. ovarian cancer, breast cancer, and colorectal cancer) due to efficacy, safety or other unpredictable factors even after earlier clinical results have been positive; (ii) the Phase 2 data for NKTR-102 in breast cancer in this press release remain subject to audit and confirmation procedures, and the final results may change materially and adversely after such procedures are completed; (iii) additional important data will be reported by Nektar in the future regarding the Phase 2 NKTR-102 clinical study in metastatic breast cancer including but not limited to final progression-free survival and overall survival and therefore the complete and final results for this study may diff
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ... ("Biotie") to end the option held by Biotie to ... further development of NRL-1 (intranasal diazepam) for pediatric and ... Over the past year, Biotie has advanced the ... preparation for the pivotal clinical work required for NDA ...
(Date:7/10/2014)... Integrated Silicon Solution, Inc. (Nasdaq: ... IC solutions, today announced that it will host its ... 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) to ... third quarter ended June 30, 2014. To ... 6:50 a.m. Pacific time on July 24, 2014.  The ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Health, Inc. (Nasdaq: GHDX ) today announced plans ... improving the quality of diagnosis, communication and support for millions ... genetic conditions.   The subsidiary is expected to be established by ... 2013.  The new venture will be led by Randy Scott, ...
... 2012 TeDan Surgical Innovations , industry leader ... Phantom Series MIS Anterior Hip Retractor System . ... adjustable surgical arms with attachable retractors, enabling surgeons to ... a surgical assistant. Dr. Lawrence Menendez ...
Cached Medicine Technology:Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4New Minimally Invasive Hip Retractor Revolutionizes Anterior Hip Replacement Procedures 2
(Date:7/12/2014)... "The second toes cross over the big toes ... shoes," said an inventor from East Hartford, Conn. This gave ... happening. , He then created a prototype of the Comfort ... and big toes from overlapping. This avoids discomfort and pain, ... easy to use, it's ideal for people with foot problems, ...
(Date:7/12/2014)... 12, 2014 Using and carrying around ... two inventors from Ashland, Va., decided that there needed ... inspired us to conceive of our design," he said. ... KIDNEY KOVER, which provides an inconspicuous way to use ... as well as promotes comfort and peace of mind. ...
(Date:7/12/2014)... July 12, 2014 For those who are ... can readily absorb the nutrients in food. The enzymes literally ... are small enough to be absorbed by human bodies. According ... lack of enzymes in regular food is the cause of ... that was started by Michelle DelPresto, a mother of 3 ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview ... health questions. Paddock tackles topics including main men's ... live longer than men, and testosterone replacement therapy, among ... featured on Doylestown Hospital’s website, Dr. Brad Paddock ... age. If you notice pain, bulging, or asymmetry in ...
(Date:7/12/2014)... 2014 Dubai is buzzing with the ... heading to the UAE. The National Basketball Association’s ... in the UAE from 28-31 October to lead the ... diabetes awareness. The event is being organized by Maven ... management company based in Dubai. The announcement was made ...
Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3
... ... customers with an advanced BlackBerry® smartphone paging solution. Onset METAMessage® enables Indiana Paging Network ... RIMM) via their current pager number and eliminate the need to carry two devices. ... (PRWEB) April ...
... the number of preventable patient injuries in California hospitals ... drop in malpractice claims against physicians, according to a ... Researchers studied both medical malpractice claims and adverse events ... that changes in the frequency of adverse events were ...
... Experimental treatment offers hope against cancer that returns after castration ... that a new hormone treatment could be a weapon for ... that,s resistant to surgical removal of the testicles. , ... new drug treatments have been completed, however. At this point, ...
... ... comprehensive and successful anti-obesity program, First Lady Michelle Obama’s “Let’s Move” campaign must ... , ... (Vocus) April 14, 2010 -- To be a truly comprehensive and successful ...
... , ... the impact of statins on the progression of multiple sclerosis found a lower incidence of ... disease as compared to a placebo. , ... (Vocus) April 14, 2010 -- A UCSF-led study examining the impact of statins ...
... unsavory-sounding name "corn smut" wields different weapons from its ... it infects. The discovery by Stanford researchers marks the ... pathogen. The finding upends conventional notions of how ... approaches to fighting disease not only in plants but ...
Cached Medicine News:Health News:Indiana Paging Network and Onset Technology Partner to Deliver Paging Messages to Blackberry Smartphones 2Health News:Indiana Paging Network and Onset Technology Partner to Deliver Paging Messages to Blackberry Smartphones 3Health News:Better patient safety linked to fewer medical malpractice claims in California 2Health News:Hormone Therapy May Fight Resistant Prostate Cancer 2Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 2Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 3Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 4Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 2Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 3Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 4Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 2Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 3Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 4
... The ISOPLATER® is an automatic petri ... streak and stack up to 180 ... Automated streaking results in substantial cost ... improves isolation rates, standardizes streaking procedures ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
... by Laborie, a leading producer ... credible tracings. ICS recognized Urodynamics ... parameters. Designed especially for the ... to be quick, efficient and ...
... diagnostic capabilities combined with ease of use ... in its class. Ideal for office or ... system for Uroflowmetry, cystometry, leak point pressure, ... are available which make the OM-5 flexible ...
Medicine Products: